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Obesity and associated disorders such as metabolic syndrome and type 2 diabetes (T2D) have reached
epidemic proportions. Several natural products have been reported as Peroxisome Proliferator-Activated
Receptor (PPAR) agonists, functioning as lead compounds towards developing new anti-diabetic drugs
due to adverse side effects of existing PPAR drugs. We recently isolated and identified (7E)-9-
oxohexadec-7-enoic acid (1) and (10E)-9-oxohexadec-10-enoic acid (2) from the marine algae Chaeto-
ceros karianus. Herein we report the total synthesis, pharmacological characterization, and biological
evaluations of these naturally occurring oxo-fatty acids (oFAs). The syntheses of 1 and 2 afforded suffi-
cient material for extensive biological evaluations. Both oFAs show an appreciable dose-dependent
activation of PPARa and -g, with EC50 values in the micromolar range, and an ability to regulate
important PPAR target genes in hepatocytes and adipocytes. Moreover, both 1 and 2 are able to drive
adipogenesis when evaluated in the Simpson-Golabi-Behmel syndrome (SGBS) pre-adipocyte cell model,
but with lowered expression of adipocyte markers and reduced lipid accumulation compared to the drug
rosiglitazone. This seems to be caused by a transient upregulation of PPARg and C/EBPa expression.
Importantly, whole transcriptome analysis shows that both compounds induce anti-diabetic gene pro-
grams in adipocytes by upregulating insulin-sensitizing adipokines and repressing pro-inflammatory
cytokines.
© 2018 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Obesity and associated disorders, such as metabolic syndrome
and type 2 diabetes (T2D), constitute a serious health problem. The
WHO estimates that there are more than 2 billion overweight
adults worldwide, half of whom are clinically obese [1]. Over 300
million people suffer from T2D, a number that will continue to
grow due to changes in dietary patterns and a more sedentary
lifestyle. Understanding the mechanisms of metabolic control in
order to prevent and treat these disorders is therefore a top
research priority. Present anti-diabetic medications include several
drug classes, such as metformin, DPP-4 inhibitors, GLP-1 analogs/
agonists, SGLT-2 inhibitors, as well as drugs targeting the peroxi-
some proliferator-activated receptors (PPARs).Sæther).
Masson SAS. This is an open accessPPARs are nuclear receptors that heterodimerize with the reti-
noid X receptor (RXR) and regulate target gene expression in
response to lipids such as unsaturated fatty acids, phospholipids,
eicosanoids, and oxygenated fatty acids [2]. Upon ligand activation,
the PPARs undergo conformational changes that facilitate the
dissociation of transcriptional co-repressors like SMRT and NCoR
[3,4], and recruitment of transcriptional co-activators and co-
activator complexes, which include factors such as p300/CBP,
SRC-1, and PGC-1a [4,5]. Additionally, posttranslational modifica-
tions alter the structural conformation of the receptors thereby
modifying the affinity for co-regulators that determine whether a
target gene is induced or repressed. In humans the PPAR isoforms
PPARa (NR1C1) and -g (NR1C3) are mainly expressed in liver and
adipose tissue, respectively, while PPARd (NR1C2) is more ubiqui-
tously expressed [6,7]. When PPARg is ligand-activated it induces
adipocyte growth and differentiation by transcriptionally regu-
lating target genes involved in lipogenesis and lipid storage [8e10].article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
Scheme 1. Reagents and conditions: (a) (COCl)2, DMSO, Et3N, CH2Cl2, 81%; (b) n-BuLi, THF, 78 C, 1ebromohexane; (c) 4, THF, 53% (two steps); (d) Lipase from Pseudomonas
cepacia, pH¼ 7.2, 64%; (e) TBSCl, imidazole, MeCN, 90%; (f) Mg, I2 cat., THF; (g) (E)-2-octenal, THF, 70% (two steps); (h) TBSCl, imidazole, DMF, 91%; (i) TFA, H2O, THF, 65%; (j) Dess-
Martin periodinane, NaHCO3, CH2Cl2; (k) NaClO2, NaH2PO4, MeCN, 2-methyl-2-butene, H2O; (l) TBAF, THF, 67% (three steps); (m) MnO2, Celite, CH2Cl2, 15%.
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through upregulation and secretion of adipokines such as adipo-
nectin and leptin from adipose tissue [11]. In parallel, PPARa in-
creases lipid uptake and energy expenditure in liver by
upregulating gene targets involved in fatty acid transport, activa-
tion and oxidation [12,13]. We recently identified the two isomeric
oxo-fatty acids (7E)-9-oxohexadec-7-enoic acid (1) and (10E)-9-
oxohexadec-10-enoic acid (2) from the marine algae Chaetoceros
karianus, and demonstrated that they display dual PPAR a/g agonist
activity [14]. Several synthetic PPAR drugs are already in clinicaluse, like the lipid-lowering fibrates, acting as PPARa activators, and
the anti-diabetic thiazolidinediones (TZDs), targeting PPARg.
However, some of the isoform-specific PPAR agonists like clofibrate,
rosiglitazone and pioglitazone have demonstrated adverse effects
such as hepatotoxicity [15,16], pulmonary edema [17], myocardial
infarction [18], weight gain [19], reduced bone density [20], and
bladder and prostate cancer [21,22]. A suggested way out has been
to identify natural products as candidate compounds with potency
for both PPARa and -g, aiming at maximizing the beneficial effects,
while minimizing the adverse. Several promising dual agonists
Fig. 1. Structure of (7E)-9-oxohexadec-7-enoic acid (1) and (10E)-9-oxohexadec-10-
enoic acid (2), (9Z,11E,13S)-13-Hydroxyoctadeca-9,11-dienoic acid (13S-HODE), and
(9S,10E,12Z)-9-Hydroxyoctadeca-10,12-dienoic acid (9S-HODE).
T. Sæther et al. / European Journal of Medicinal Chemistry 155 (2018) 736e753738display significant improvement in both glycemic as well as dysli-
pidemic parameters with no evidence of conventional side effects
[23e27]. In this aspect, natural products are of interest. Some
natural occurring fatty acid PPAR-agonists are depicted below.
In this paper we report the synthesis, pharmacologicalFig. 2. The synthetic oxo-fatty acids (7E)-9-oxohexadec-7-enoic acid (1) and (10E)-9-oxo
response of 1 (7E)-9-OHE and 2 (10E)-9-OHE, compared to pirinixic acid, rosiglitazone and pa
DBD-NR-LBD chimeric constructs in COS-1 cells, using LBD from human PPARa and PPARg,
dehydrogenase (LDH) in media or (D) by running XTT assays. The results are shown as m
relative light units.
Table 1







Pirinixic acid 39 n.d.
Rosiglitazone n.d. 0.2
Palmitic acid 35 n.d.characterization, and extensive biological evaluations of the oxo-
fatty acids 1 and 2.
2. Results and discussion
2.1. Chemistry
The synthesis towards (7E)-9-oxohexadec-7-enoic acid (1)
started with known methyl 7-hydroxyheptanoate (3) [28,29]
(Scheme 1). Swern oxidation of 3 afforded 4 in 81% yield. Next the
commercially available phosphorane 5was treated with n-BuLi and
1-bromohexane to afford the hexyl substituted intermediate of 5
that was reacted with aldehyde 4 in an E-selective Wittig-reaction.
This gave methyl (E)-9-oxohexadec-7-enoate (6) in 53% yield from
3. The hydrolysis of 6 to 1 provedmore challenging than anticipated
as several conditions failed to produce the natural product 1 due to
the formation of polymeric material. However, the acid 1 was
formedwhen 6was added to a phosphate buffer solution (pH¼ 7.2,
37 C) containing lipase from Pseudomonas cepacia. The spectral
data confirmed the structure of 1 with the E-configuration
(J¼ 15.9 Hz).
The synthetic approach for making 1 was not amendable for
making (10E)-9-oxohexadec-10-enoic acid (2). The a,b-unsaturated
ketone moiety in 2 was proven to be quite labile. Hence, an alter-
native synthetic route was developed. First, known 7 [30] washexadec-10-enoic acid (2) activate PPARa and -g and show low cytotoxicity. Dose-
lmitic acid on (A) PPARa activity and (B) PPARg activity. The assays were runwith Gal4-
respectively. (C) Corresponding cytotoxicity data were obtained by measuring lactate
ean ± SEM. The data represent three biological replicates run in quadruplicates. RLU:









Fig. 3. The oxo-fatty acids 1 and 2 display PPARa/g dual specificity. The assays were
run with Gal4-DBD-NR-LBD chimeric constructs in COS-1 cells, using the ligand
binding domain (LBD) from human nuclear receptors. The doses used were 0, 25 and
50 mM of 1 (7E)-9-OHE and 2 (10E)-9-OHE, respectively. The results are shown as
mean ± SEM. The data represent three biological replicates run in quadruplicates. RLU:
relative light units. *p < 0.05, **p < 0.05, ***p < 0.001.
Fig. 4. The oxo-fatty acids 1 and 2 activate human natural promoters in a PPAR/
PPRE-depend manner. COS-1 cells were transfected with full-length PPARa, the het-
erodimerization partner RXRa and a CPT1A-driven reporter, with or without a func-
tional PPAR recognition element (PPRE) or PPARg, RXRa and a PLIN1-driven reporter,
with (black bars) or without (white bars) a functional PPRE. The cells were then treated
with 1 (7E)-9-OHE or 2 (10E)-9-OHE for 18 h. The results are shown as mean ± SEM.
The data represent three biological replicates run in quadruplicates. RLU: relative light
units. ***p < 0.001.
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solution of commercially available (E)-2-octenal. This gave theallylic alcohol 8. Hence, alcohol 8 was converted into the bis-TBS
ether using standard conditions (TBSCl, imidazole) that was
mono-deprotected using aqueous TFA. This gave 9 that was
oxidized to the aldehyde using the Dess-Martin reaction. A
Lindgren-Pinnick oxidation of the formed aldehyde followed by
deprotection of the TBS-group afforded 10. Oxidation of the allylic
alcohol was best achieved using electrolytically activated MnO2
that gave the natural product 2, albeit in 15% yield. The spectral data
confirmed the structure of 2. All efforts to improve the yield of 2
were fruitless. The total yield of 2 was 4% over nine steps from 8-
bromooctan-1-ol.
2.2. Dose-response and toxicity
We started by evaluating oxo-fatty acid (oFA) 1 and 2 with
respect to PPARa and PPARg agonist activity using GAL4-LBD fusion
constructs and GAL4-responsive Luciferase reporters in COS-1 cells.
The oFA activity profile was compared with rosiglitazone and pir-
inixic acid (positive controls) and palmitic acid (negative control).
Cytotoxicity was determined simultaneously assaying for lactate
dehydrogenase (LDH) in the cell media. In addition, cytotoxicity
was assessed using standard XTT assays. The dose-response curves
are shown in Fig. 2 and summarized with corresponding EC50-
values in Table 1.
As can be seen both oFAs show an appreciable PPAR agonist
dose-response, with EC50-values in the micromolar range (Fig. 2;
Table 1). At the same time the cell toxicity, as measured by lactate
dehydrogenase leakage (LDH) and reduced metabolic NAD(P)H flux
(XTT), is none to moderate in the same concentration range
(10e30 mM). With respect to PPARa agonism, both 1 and 2 dis-
played EC50-values and agonist activity comparable to pirinixic acid
(WY-1464). However, when assaying 1 and 2 in the PPARg activity
assay, their EC50-values were approximately 50 fold higher and
their PPARg agonist activities about 50% lower of that observed
with rosiglitazone (BRL 49653; Fig. 2).
2.3. Selectivity
We next addressed the selectivity of the two oxo-fatty acids
with respect to nuclear receptor agonist activity. To this end we
transfected COS-1 cells with GAL4-LBD fusions of human PPARa, -d,
-g, LXRa, -b, and RXRa, and treated them with increasing concen-
trations of the oFAs. Both natural products were able to activate
PPARa and -g in the range of 25e50 mM, while neither of them
activated the LXRs or RXRa (Fig. 3). A small but significant PPARd
agonist activity was observed with 50 mM of 2.
To be able to study the agonist activity of 1 and 2 in a more
relevant context we expressed full-length human PPARa and eg
together with RXRa in COS-1 cells and assayed their transactivity
on human CPT1A- and PLIN1-driven luciferase reporters in the
presence or absence of the oxo-fatty acids. As can be seen in Fig. 4
both 1 and 2were able to activate the PPARa-target gene promoter
CPT1A, while only 1 activated the promoter of PLIN1, a bona fide
PPARg target gene. This activation was dependent of functional
PPAR response elements (PPREs).
2.4. Activation of endogenous PPAR target genes
As both oxo-fatty acids displayed PPAR agonism in vitro, we
asked whether 1 and 2 were able to activate fully chromatinized
PPAR target genes in the human hepatocellular carcinoma cell line
Huh7. Huh7 cells express both PPARa and eg [31] (Ct: 26.3 and
24.6, respectively at baseline), but is often used in combination
with PPARa agonist to assess regulation of liver-specific PPARa
target genes. While both 1 and 2 were able to induce CPT1A and
Fig. 5. The oxo-fatty acids 1 and 2 activate endogenous target genes in human hepatocarcinoma cells. Huh7 cells were stimulated with 50 mM of 1 (7E)-9-OHE, 2 (10E)-9-OHE
or pirinixic acid (PIRI) for 24 h. Gene expression was analysed by qPCR using specific SYBR green primers. The results are shown as mean ± SEM. The data represent 3 biological
replicates run in duplicates. *p < 0.05, **p < 0.01, ***p < 0.001.
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upregulated significantly by 2 but to very low levels. We were
surprised to find that ACOX1, a classical PPARa target gene did not
respond to any of the treatments. Several of the assayed target
genes displayed a weak but significant downregulation (Fig. 5).
Whether this was due to cytotoxic effects were not studied further.2.5. Adipocyte differentiation
Turning our focus to adipocyte-specific target gene activation,
we took advantage of the human Simpson-Golabi-Behmel syn-
drome (SGBS) pre-adipocyte cell line [32], and differentiated them
into adipocytes using an 8 days differentiation protocol as
described in the experimental section. On day 8 we either stimu-
lated the cells with 1 or 2, or rosiglitazone. As can be seen in Fig. 6
both 1 and 2 induce the expression of CPT1A, while only 2was able
to upregulate ANGPTL4 expression. Oxo-fatty acid 1 and 2 were not
able to induce classical adipocyte markers, such as PLIN1, FABP4 and
ADIPOQ. Even rosiglitazone failed to induce these genes any further.
The reason for this is probably that differentiated SGBS cells already
have a high expression of these genes. As an exception to this, UCP1
was induced 10 times compared to baseline by rosiglitazone.
To address a potential role for 1 and 2 in adipocyte differentia-
tion we compared the adipogenic potential of both compounds to
rosiglitazone, by exchanging the classical PPARg agonist with 1, 2 or
DMSO the first 4 days of the differentiation protocol. On day 0, 4, 8
and 12 cells were either harvested for RNA isolation, to monitor the
expression of target genes, or stained with Oil-Red-O to follow the
inclusion of neutral lipids in lipid droplets.Interestingly both 1 and 2 increased the number of cells with
adipocyte-like, multilocular morphology, as well as the total vol-
ume of lipid droplets (no. of droplets size). As expected, rosigli-
tazone was much more potent in inducing adipogenesis.
Interestingly, the droplets formed during treatment with 1 seemed
to be slightly bigger than the ones seen with rosiglitazone and 2
(Fig. 7, day 12). To evaluate the gene regulatory events underlying
the morphological changes we assayed 20 genes relating to adi-
pogenesis (Fig. 8), lipid storage and metabolism (Fig. 9) and adi-
pokine signalling and browning (Fig. 10) using quantitative PCR.
Both 1 and 2 were able to induce the classical adipogenic factors,
PPARG, CEBPA and CEBPB (Fig. 8). The onset of the adipogenic gene
program is also reflected in the upregulation of PLIN1, FABP4, CD36
and SCD1 which play important roles in fatty acid metabolism,
transport and storage. This was seen with both oFAs (Fig. 9).
However, the expression of most of these genes seem to be 5e10-
fold lower on day 8e12 after stimulation with 25 mM 1 and 2
thanwith rosiglitazone. This might be related to what seems to be a
transient induction of several important adipogenic driver genes
when treating the cells with 1 and 2 (Fig. 8). Here gene expression
peaked at day 4, while the rosiglitazone-treated cells were able to
support a stable or increased expression of e.g. PPARG and CEBPA for
the whole duration of the experiment. Part of the same pattern can
be seen in Fig. 10 with the adipokines and thermogenic factors. Still,
it should be noted that both 1 and 2 significantly upregulate the
expression of adiponectin (ADIPOQ) and the mitochondrial brown
fat uncoupling protein 1 (UCP1) over the 12 day differentiation
period (Fig. 10).
Fig. 6. The oxo-fatty acids 1 and 2 activate endogenous target genes in human adipocytes. SGBS cells were differentiated following standard protocol. On day eight the cells
were stimulated with either 25 mM 1 (7E)-9-OHE, 25 mM 2 (10E)-9-OHE, or 2 mM rosiglitazone (ROSI) for 24 h. Gene expression was analysed by qPCR using specific SYBR green
primers. The results are shown as mean ± SEM. The data represent three biological replicates run in duplicates. *p < 0.05, **p < 0.01, ***p < 0.001.
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To get a comprehensive view of the differential, transcriptional
changes occurring during adipocyte differentiation, we sequenced
RNA from SGBS cells differentiated for 8 days in medium supple-
mented with oxo-fatty acid 1, 2 or rosiglitazone. Data from the
treated cells were compared to SGBS cells at day 0. As can be seen
from the Venn diagrams in Fig. 11A there was a significant overlap
between the genes regulated by 1 and 2, with 82.2% among the top
500 upregulated and 85.8% overlap among the top 500 down-
regulated genes. The overlap between rosiglitazone and the oxo-
fatty acids was 42.0% and 58.4% for the same set of upregulated
and downregulated genes, respectively. Pathway enrichment
analysis made based on the KEGG collection displayed a significant
overrepresentation of upregulated genes involved in e.g. PPAR
signalling (hsa03320), fatty acid biosynthesis (hsa00061), and
steroid biosynthesis (hsa00100) for 1 and 2, as well as for rosigli-
tazone (Fig. 11B). Interestingly, biosynthesis of unsaturated fatty
acids and fatty acid elongation (hsa00062 and hsa01041) seem to
be overrepresented only in the rosiglitazone gene set. When ana-
lysing the downregulated genes, pathways such as extra cellular
matrix-receptor interaction (hsa04512), TNF signalling (hsa04668),
and AGE-RAGE signalling in diabetic complications (hsa04933)
stood out (Fig. 11C). The principal component analysis made, based
on the 8274 differentially expressed genes (DEGs) in our dataset
showed that both oxo-fatty acid and rosiglitazone-treated cells
differ significantly from the day 0 cells (Fig. 11D). Interestingly, the
transcriptomes from oxo-fatty acid 1 cells cluster with the oxo-fatty
acid 2 cells, and separate from the rosiglitazone transcriptomes
when the total variance is explained using these principal com-
ponents. Taking a closer look at the genes in the top tier enrichedpathways (Fig. 12) the pattern from the differentiation experiments
again becomes evident (Figs. 8e10). Even though both oFAs and
rosiglitazone drive the expression of most genes in the sets in the
same direction, the potency of 1 and 2 are lower, leading to a
gradual decrease in expression and an earlier turning point from
up-to downregulation (PPAR signalling) or vice versa (ECM-re-
ceptor interaction). The same is also seen for genes involved in fatty
acid biosynthesis, adipokine signalling, biosynthesis of unsaturated
fatty acids, and AGE-RAGE signalling in diabetic complications
(Suppl. Fig. 1). In the pathway analysis shown in Fig. 12 and
Suppl. Fig. 1, all genes in the KEGG gene set were included, inde-
pendent of expression level. To get a better understanding of the
difference between the rosiglitazone treated cells and the cells
treated with 1 and 2, we plotted the top 500 expressed genes in the
rosiglitazone transcriptome in falling order and compared them to
the same genes in the oFA transcriptomes (Fig. 13). Most of the
genes express approximately 10-fold lower in the cells treated with
1 and 2, resulting in the veil-like clustering below the rosiglitazone
line. Interestingly, ten outliers are easily distinguishable for both
treatments (Fig. 13; red circles).
A closer look at Table 2, listing these genes, shows that six out of
seven overexpressed genes relate to extra cellular matrix. This
probably reflects the more fibroblast-like properties of these cells,
and indicates a restricted or delayed adipogenigenesis. The reduced
levels of PDK4 and PDE3B point in the same direction (Table 2). That
being said, lower levels of phosphodiesterase 3 might be beneficial
as this would lower the anti-lipolytic effect of insulin and enable
full induction of UCP1 expression and lipolysis in brown adipocytes
in response to adrenergic stimulus [33,34].
Our data clearly show that while being able to activate both
PPARa and PPARg, oxo-fatty acids 1 and 2 have a reduced
Fig. 7. The oxo-fatty acids 1 and 2 drive adipocyte differentiation, but to a lesser extent than rosiglitazone SGBS cells were differentiated in Quickdiff and 3FC medium for 4 and
8 days, respectively, following standard protocol. The quickdiff medium was supplemented with either 25 mM 1 (7E)-9-OHE, 25 mM 2 (10E)-9-OHE, or 2 mM rosiglitazone. DMSO
(0.025%) and BSA (4.2 mM) were used as negative control. Adipocyte differentiation was monitored by staining of neutral lipids using Oil-Red-O. The images are representative for
three biological replicates run in duplicates.
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for their lower potency by adding twice their EC50-values in the
stimulation- and differentiation cocktails, their reduced efficacy,
especially with respect to PPARg activity (Fig. 2), restricted gene
activation and delayed adipogenigenesis (Figs. 7e10). This may at
first glance be interpreted as a disadvantage. However, as many of
the known side effects of the thiazolidinediones (TZDs) have been
attributed to their potency and efficacy as classical PPARg-specific
agonists, this may in fact be an advantage. The strong adipogenic
potential of the TZDs evidently contributes to the weight gain
associated with the use of this of this type of anti-diabetic drugs[35,36]. While 1 and 2 are able to drive adipogenesis, their ability to
activate target genes and support lipid storage in adipocytes is
several fold lower than that of rosiglitazone (Figs. 7e9). Whether
this is all due to reduced lipid synthesis or also reduced synthesis of
lipid droplet coating factors, like the PLIN family (Fig. 14), is difficult
to know.
The continuous increase in expression for many of the PPARg
target genes observed with TZD-stimulated adipogenesis (Figs. 9
and 10) has been reported in numerous papers, and is proposed
to be caused by these agonists' ability to induce the biosynthesis of
endogenous PPARg ligands [37e39]. As unsaturated and elongated
Fig. 8. The oxo-fatty acids 1 and 2 induce an adipogenic gene program in SGBS cells. SGBS cells were differentiated in Quickdiff and 3FC medium for 4 and 8 days, respectively,
following standard protocol. The quickdiff mediumwas supplemented with either 25 mM 1 (7E)-9-OHE, 25 mM 2 (10E)-9-OHE, or 2 mM rosiglitazone. DMSO or DMSO:BSA were used
as control. Gene expression was analysed by qPCR using specific SYBR green primers with RNA from cells harvested on day 0, 4, 8, and 12 (D0-D12). The results are shown as
mean ± SEM. The data represent minimum 3 biological replicates run in duplicates. *p < 0.05, **p < 0.01, ***p < 0.001.
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Fig. 9. The oxo-fatty acids 1 and 2 induce gene involved in lipid metabolism and storage in SGBS cells. SGBS cells were differentiated in Quickdiff and 3FC medium for 4 and 8
days, respectively, following standard protocol. The quickdiff medium was supplemented with either 25 mM 1 (7E)-9-OHE, 25 mM 2 (10E)-9-OHE, or 2 mM rosiglitazone. DMSO or
DMSO:BSAwere used as control. Gene expressionwas analysed by qPCR using specific SYBR green primers with RNA from cells harvested on day 0, 4, 8, and 12 (D0-D12). The results
are shown as mean ± SEM. The data represent minimum three biological replicates run in duplicates. *p < 0.05, **p < 0.01, ***p < 0.001.
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Fig. 10. The oxo-fatty acids 1 and 2 induce adipokines and browning factors. SGBS cells were differentiated in Quickdiff and 3FC medium for 4 and 8 days, respectively, following
standard protocol. The quickdiff mediumwas supplemented with either 25 mM 1 (7E)-9-OHE, 25 mM 2 (10E)-9-OHE, or 2 mM rosiglitazone. DMSO or DMSO:BSAwere used as control.
Gene expression was analysed by qPCR using specific SYBR green primers with RNA from cells harvested on day 0, 4, 8, and 12 (D0-D12). The results are shown as mean ± SEM. The
data represent minimum 3 biological replicates run in duplicates. *p < 0.05, **p < 0.01, ***p < 0.001.
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proposed endogenous PPAR ligands, e.g. PUFAs, prostaglandins and
other oxidized eicosanoids, it is intriguing that two of themetabolic
pathways necessary to produce such molecules (hsa00062:
biosynthesis of unsaturated fatty acids; hsa01041fatty acid elon-
gation) are underrepresented in the top tire DEGs from the oxo-fatty acid-stimulated cells (Fig. 11). The oxo-fatty acids, which
structurally resemble the linoleic acid metabolites 9S-HODE and
13S-HODE [40], and even more so the corresponding oxo-fatty
acids 9-oxo-ODE and 13-oxo-ODE [41], are still not able to sup-
port a PPAR-driven, self-reinforcing adipogenesis. Whether this is
due to 1 and 2 not being able to bind covalently to PPARg as other
T. Sæther et al. / European Journal of Medicinal Chemistry 155 (2018) 736e753746
T. Sæther et al. / European Journal of Medicinal Chemistry 155 (2018) 736e753 747a,b-unsaturated ketones [41,42] or if it a stability issue, should be
the focus of future structure-activity-relationship studies.
The reduced PPARg agonistic activity of the oFAs is still strong
enough to induce a robust expression of leptin (LEP) and the
insulin-sensitizing adipokine adiponectin (ADIPOQ) in the adipo-
cyte model (Fig. 10). At the same time their PPARa agonistic activity
triggers fatty acid catabolism by inducing genes involved in b-
oxidation, like CPT1A and ACSL3 in hepatocytes (Fig. 5) and CPT1A in
mature adipocytes (Fig. 6). This provides the oFAs with additional
beneficial effects, known to be inherent properties of other PPARa/
g dual agonists [23,25,27,43]. Certain adipokines contribute to the
development of obesity-associated insulin resistance, and studies
on the link between obesity and insulin resistance have shown that
there is an extensive crosstalk between adipocytes and immune
cells in the adipose tissue (AT) [44,45]. Pro-inflammatory cytokines
like IL-6, IL-1b and TNFa are mostly produced and secreted by
macrophages infiltrating the AT. However as part of the crosstalk,
macrophage-derived factors potently stimulate adipocytes to pro-
duce pro-inflammatory cytokines [46e48]. On the other side,
activation of PPARg by TZDs is shown to modulate this
inflammatory-like state by suppressing cytokine production
[49,50]. Thus, it is agreeable that TNF signaling (hsa04668) is one of
the top three overrepresented pathways among the differentially
downregulated genes (Fig. 11). As can be seen in Fig. 15, both oFAs
and rosiglitazone are repressing cytokine production. Interestingly,
IL-1b seems to be an exception: only 1 and 2 are able to repress the
IL1B gene expression, while rosiglitazone seems to have no effect
(Fig. 15). Since IL-1b is a major pro-inflammatory cytokine involved
in AT metainflammation, and known to reduce adipose insulin
sensitivity by downregulating IRS1 and GLUT4 expression [51,52], it
is tempting to suggest that transcriptional regulation of this inter-
leukin 1 B is another potential advantage of the oxo-fatty acids.
Indeed IRS2 expression increases with both 1 and 2, while there is a
tendency towards increased expression of IRS1 and SLC2A4 (GLUT4)
(Fig. 16).
The adverse effects reported with both PPARa-activating
fibrates and PPARg-activating thiazolidinedione, such as hepato-
toxicity, pulmonary edema, myocardial infarction, weight gain,
reduced bone density, and bladder and prostate cancer [15e22]
were not addressed further in this paper. To proceed in this matter
we would have to initiate in vivo studies in mice, which given the
current in vitro cytotoxicity profile of 1 and 2 was not alternative.
Certain of the reported side effects, like cancers of the bladder and
prostate, is difficult to detect in animal models. Moreover, clinical
trials are often too short to detect drug-related tumorigenesis.
Therefore, the carcinogenic potential of most compounds is eval-
uated based on the extrapolation of minimum 2-year studies in rats
or mice. Before testing the oFAs in long term in vivo experiments,
less cytotoxic analogues would have to be synthesised and
characterized.3. Conclusion
Through the synthesis, pharmacological characterization, and
biological evaluations of the oxo-fatty acids (7E)-9-oxohexadec-7-
enoic acid (1) and (10E)-9-oxohexadec-10-enoic acid (2), we haveFig. 11. Adipocyte transcriptomics. RNA from SGBS cells differentiated for 8 days in me
rosiglitazone (all treatments n¼ 2e4), were sequenced on a Illumina NextSeq500, using stran
reads were aligned, counted and normalized as Reads Per Kilobase of transcript per Million
from the three treatments. (B) KEGG pathway enrichment analysis of the top 500 upregula
percent overlap with the KEGG gene sets. Minimum overlap with input list: 3. p-value cut
Principal component 1 and 2 explains 55.6% and 23.6% of the total variance, respectively. Pr
will fall inside with a probability of 0.95.shown that both compounds are semi-potent dual PPARa/g ago-
nists. While being derived from a marine alga, both oFAs regulate
important PPAR target genes in human hepatocytes and adipocytes.
Transcriptome analyses show that both compounds activate anti-
diabetic gene programs in adipocytes by upregulating insulin-
sensitizing adipokines and repressing pro-inflammatory cyto-
kines. Simultaneously, they do not accumulate lipids in the adipo-
cytes to the same extent as the classical thiazolidinediones.
Together these features make the oxohexadecenoic acids inter-
estingmolecular scaffolds for designing new ligandswith improved
stability and a better toxicity profile to test in animal models




Methyl 7-hydroxyheptanoate (3) was synthesized using litera-
ture protocols [28,29,53,54]. The physical and spectral data of 3
were in full agreement with those reported in the literature.
4.1.2. Methyl (E)-9-oxohexadec-7-enoate (6)
Phosphorane 5 (190mg, 0.60mmol, 1.18 equiv.) in THF (4mL)
was added n-BuLi (0.41mL, 1.6M in hexane, 1.30 equiv.) at 78 C
and stirred for 20min. 1-Bromohexane (83mg, 0.51mmol, 1.00
equiv.) dissolved in CH2Cl2 (0.4mL) was added dropwise and the
solution was allowed to warm up to room temperature overnight.
The reaction mixture was diluted with H2O (10mL) and extracted
with CH2Cl2 (3 10mL). The combined organic layers were dried
(Na2SO4), before being concentrated in vacuo. The crude product
was dissolved in CH2Cl2 (1.5mL) and aldehyde 4 (80mg, 0.51mmol,
1.00 equiv.) in CH2Cl2 (1.0mL) was added. The solution was stirred
overnight before being concentrated in vacuo. The crude product
was purified by column chromatography on silica (hexanes/EtOAc
9:1) to afford the title compound 6 as a colourless oil. Yield: 75mg
(53%). TLC (hexanes/EtOAc 9:1, KMnO4 stain): Rf¼ 0.12; 1H NMR
(300MHz, CDCl3) d 6.82 (dt, J¼ 15.9, 6.9 Hz, 1H), 6.10 (dt, J¼ 15.9,
1.5 Hz, 1H), 2.53 (t, J¼ 7.4, 2H), 2.33 (t, J¼ 7.4, 2H), 2.22 (td, J¼ 7.5,
1.5 Hz, 2H), 1.72e1.57 (m, 4H), 1.56e1.42 (m, 2H), 1.42e1.25 (m,
10H), 0.90 (t, J¼ 6.6, 3H); 13C NMR (101MHz, CDCl3) d 201.0, 174.2,
146.8, 130.6, 51.6, 40.4, 34.0, 32.3, 31.9, 29.4, 29.3, 28.8, 27.9, 24.8,
24.5, 22.8, 14.2. HRMS (TOF ESþ) Exact mass calculated for
C17H30NaO3 [MþNa]þ: 305.2092, found: 305.2102.
4.1.3. (E)-9-Oxohexadec-7-enoic acid (1)
The methyl ester 6 (20mg, 0.07mmol) was dissolved in phos-
phate buffer (pH¼ 7.2, 0.7mL) and heated to 37 C. Lipase from
Pseudomonas cepacia (10mg) was added and the reaction was
stirred at ambient temperature for 24 h. The mixture was and
extracted with CH2Cl2 (3 10mL). The combined organic layers
were dried (Na2SO4), before being concentrated in vacuo. The crude
product was purified by column chromatography on silica (hex-
anes/EtOAc 97.5:2.5, then 90:10) to afford the title compound 1 as a
white solid. Yield: 12mg (64%). TLC (hexanes/EtOAc 7:3, KMnO4
stain): Rf¼ 0.12; 1H NMR (400MHz, CDCl3) d 6.80 (dt, J¼ 15.9,dium supplemented with either 25 mM 1 (7E)-9-OHE, 25 mM 2 (10E)-9-OHE or 2 mM
d-specific TruSeq RNA Sample Preparation, generating 2 75 bp paired-end reads. The
mapped reads (RPKM). (A) Venn diagrams of the top 500 up- or downregulated genes
ted and (C) downregulated genes, relative to day 0, displayed in falling order based on
off: p< 0.01. (D) Principal Component Analysis (PCA) of the 8274 DEGs in our dataset.
ediction ellipses represent the area for which a new observation from the same group
T. Sæther et al. / European Journal of Medicinal Chemistry 155 (2018) 736e7537486.9 Hz, 1H), 6.09 (d, J¼ 15.9 Hz, 1H), 2.52 (t, J¼ 7.5 Hz, 2H), 2.36 (t,
J¼ 7.4 Hz, 2H), 2.22 (qd, J¼ 7.0, 1.5 Hz, 2H), 1.70e1.55 (m, 4H),
1.53e1.45 (m, 2H), 1.44e1.34 (m, 2H), 1.34e1.22 (m, 8H), 0.87 (t,
J¼ 4.8, 3H); 13C NMR (101MHz, CDCl3) d 201.1, 178.6, 146.8, 130.6,
40.4, 33.8, 32.3, 31.9, 29.4, 29.3, 28.7, 27.9, 24.5, 24.5, 22.8, 14.2.
HRMS (TOF ESþ) Exact mass calculated for C16H28NaO3 [MþNa]þ:
291.1936, found: 291.1940.
4.1.4. ((8-Bromooctyl)oxy) (tert-butyl)dimethylsilane (7)
The compound 7 was prepared essentially as previously re-
ported [30]. 8-Bromooctan-1-ol (6.00mmol, 1.25 g) was dissolved
in dryMeCN (12.0mL) and added TBSCl (6.3mmol, 0.94 g) and then
imidazole (9.00mmol, 0.630 g). The mixture was stirred under
argon for 1 h. The mixture was filtered, evaporated, and purified by
flash chromatography on silica gel (EtOAc:heptane, 49:1) to give
the known compound 7 as a colourless oil. Yield 1.74 g (90%). 1H
NMRdatawas in agreement with literature [30]. 1H NMR (400MHz,
Chloroform-d) d 3.60 (t, J¼ 6.6 Hz, 2H), 3.41 (t, J¼ 6.9 Hz, 2H), 1.85
(quint., J¼ 6.9 Hz, 2H), 1.55e1.39 (m, 4H), 1.30 (m, 6H), 0.89 (s, 9H),
0.04 (s, 6H).
4.1.5. (E)-16-((Tert-butyldimethylsilyl)oxy)hexadec-6-en-8-ol (8)
Magnesium turnings (6.40mmol, 0.154 g, 2.00 equiv.) and a
magnet were placed in a flame dried round bottomed flask that was
flushed with argon. A small amount of iodine (ca. 6mg) was added.
A solution of the bromide 7 (4.16mmol, 1.34 g, 1.30 equiv.) in dry
THF (12.0mL) was prepared, and about 2mL of this solution was
quickly added to the magnesium turnings. After a few minutes of
vigorous stirring, the reaction mixture went from clear brown to
colourless. The remaining THF-solution of bromide 7 was then
added over 5min. After 1 h the solution was cloudy and the
remaining magnesiumwas black. The mixture was cooled on an ice
bath and added a solution of (E)-2-octenal (3.20mmol, 0.403 g,1.00
equiv.) in dry THF (4.00mL) over 5min. The cooling bath was
removed and the mixture stirred for 1 h. After 1 h, the mixture was
cooled on an ice bath and quenched with sat. aq. NH4Cl (40mL).
The mixture was extracted with EtOAc (3 20mL), dried (MgSO4),
evaporated and purified by flash chromatography on silica gel
(EtOAc:heptane, 15:85) to give the desired product 8 as a colourless
oil. Yield: 0.832 g (70%). Rf¼ 0.35 (EtOAc:heptane 3:7, KMnO4-
stain). 1H NMR (400MHz, Chloroform-d) d 5.62 (m,1H), 5.44 (broad
dd, J¼ 15.4, 7.2, Hz, 1H), 4.02 (q, J¼ 6.7 Hz, 1H), 3.59 (t, J¼ 6.6 Hz,
2H), 2.07e1.95 (m, 2H), 1.59e1.22 (m, 21H), 0.89 (s, 9H), 0.88 (m,
3H), (0.04 (s, 6H). 13C NMR (101MHz, CDCl3) d 133.2, 132.4, 73.4,
63.5, 37.5, 33.0, 32.3, 31.5, 29.7, 29.7, 29.5, 29.0, 26.1 (3xC), 25.9,
25.6, 22.7, 18.5, 14.2, 5.1. Exact mass calculated for C22H46O2SiNa
[MþNa]þ: 393.3159, found 393.3159.
4.1.6. (E)-9-((Tert-butyldimethylsilyl)oxy)hexadec-10-en-1-ol (9)
Step 1. Synthesis of (E)-5-(Hept-1-en-1-yl)-2,2,3,3,15,15,16,16-
octamethyl-4,14-dioxa-3,15-disilaheptadecane. The alcohol 8
(2.18mmol, 0.805 g,1.00 equiv.) was dissolved in dry DMF (10.0mL)
and was added tert-butyl dimethylsilyl chloride (2.62mmol,
0.394 g, 1.20 equiv.) and imidazole (5.45mmol, 0.371 g, 2.50 equiv.).
After stirring for 16 h, the mixture was added sat. aq. NaHCO3
(30mL) and water (50mL), and the mixture was then extracted
with EtOAc (3 30mL), dried (MgSO4) and evaporated. The residueFig. 12. The oxo-fatty acids 1 and 2 induce a transcriptional PPAR signalling pro-
gram and downregulate genes involved in extra cellular matrix-receptor interac-
tion. RNA sequencing data (RPKM) from SGBS cells differentiated for 8 days in medium
supplemented with either 25 mM 1 (7E)-9-OHE, 25 mM 2 (10E)-9-OHE or 2 mM rosi-
glitazone (ROSI) (n¼ 2e4) were averaged and expressed as log2 fold-induction over
unstimulated cells (day 0). Gene sets were grouped based on the Kyoto Encyclopedia of
Genes and Genomes (KEGG).
Fig. 13. The fatty acids 1 and 2 slow down fibroblast-to-adipocyte transition. Top 500 expressed genes in SGBS cells (day 8) differentiated in medium supplemented with
rosiglitazone at was sorted in falling order based on RNA sequencing data (black line). The corresponding expression data from SGBS cells differentiated in medium supplemented
with 1 (7E)-9-OHE (A) and 2 (10E)-9-OHE (B) was superimposed on the same graph (grey circles). Outliers are indicated with red circles and gene symbol.
Table 2
Outliers in the Top 500 expressed gene set.
Symbol Gene name Relative G.E.a
COL3A1 Collagen type III alpha 1 chain þ
COL1A2 Collagen type I alpha 2 chain þ
FN1 Fibronectin 1 þ
COL1A1 Collagen type I alpha 1 chain þ
FSTL1 Follistatin like 1 þ
MMP2 Matrix metallopeptidase 2 þ
COL6A3 Collagen type VI alpha 3 chain þ
KRT79 Keratin 79 e
PDK4 Pyruvate dehydrogenase kinase 4 e
PDE3B Phosphodiesterase 3 B e
a Relative to rosiglitazone stimulated SGBS cells.
Fig. 14. Regulation of the lipid droplet-associated protein Perilipin family in SGBS cells.
days in medium supplemented with either 25 mM 1 (7E)-9-OHE, 25 mM 2 (10E)-9-OHE, or 2
shown as mean ± SD, and represent 2-4 biological replicates. *p < 0.05, **p < 0.01.
Fig. 15. The oxo-fatty acids 1 and 2 downregulate pro-inflammatory cytokines in SGBS
tokines from SGBS cells differentiated for 8 days in medium supplemented with either 25 mM
included for comparison. The results are shown as mean ± SD, and represent 2-4 biologica
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(E)-5-(Hept-1-en-1-yl)-2,2,3,3,15,15,16,16-octamethyl-4,14-dioxa-
3,15-disilaheptadecane as a colourless oil. Yield: 0.960 g (91%).
Rf¼ 0.50 (EtOAc:heptane 1:20, KMnO4-stain). 1H NMR (400MHz,
Chloroform-d) d 5.49 (m, 6.6 Hz,1H), 5.36 (dd, J¼ 15.4, 6.8,1H), 4.00
(q, J¼ 6.4 Hz, 1H), 3.59 (t, J¼ 6.6 Hz, 2H), 1.99 (q, J¼ 6.7 Hz, 2H),
1.60e1.21 (m, 22H), 0.89 (d, J¼ 4.4 Hz, 21H), 0.05 (s, 6H), 0.04 (s,
3H), 0.02 (s, 3H). 13C NMR (101MHz, CDCl3) d 133.9, 130.5, 74.0,
63.5, 38.7, 33.0, 32.3, 31.5, 29.8, 29.7, 29.6, 29.1, 26.1 (3xC), 26.1
(3xC), 25.9, 25.6, 22.7, 18.5, 18.5, 14.2, 4.0, 4.6, 5.1 (2xC). Exact
mass calculated for C28H60O2Si2Na [MþNa]þ: 507.4024, found
507.4023.
Step 2. Protected (E)-5-(Hept-1-en-1-yl)-2,2,3,3,15,15,16,16-
octamethyl-4,14-dioxa-3,15-disilaheptadecane (1,94mmol,Comparison of gene expression (RPKM) of PLIN1-5 from SGBS cells differentiated for 8
mM rosiglitazone. Gene expression at day 0 is included for comparison. The results are
cells. Comparison of gene expression (RPKM) of a selection of pro-inflammatory cy-
1 (7E)-9-OHE, 25 mM 2 (10E)-9-OHE, or 2 mM rosiglitazone. Gene expression at day 0 is
l replicates. **p < 0.01.
Fig. 16. Antidiabetic effects of oxo-fatty acids 1 and 2 in SGBS cells. Gene expression (RPKM) of insulin receptor substrates IRS1 and IRS2 and the glucose transporters SLC2A1 and
SLC2A4 were measured as proxies for increased insulin sensitivity and glucose uptake in SGBS cells differentiated for 8 days in medium supplemented with either 25 mM 1 (7E)-9-
OHE, 25 mM 2 (10E)-9-OHE, or 2 mM rosiglitazone. Gene expression at day 0 is included for comparison. The results are shown as mean ± SD, and represent 2-4 biological replicates.
**p < 0.01.
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fluoroacetic acid in water (4.5mL, TFA:H2O 1:9). The mixture was
stirred at ambient temperature for 3 h before it was quenched by
addition of sat. aq. NaHCO3 (50mL). The mixture was extracted
with EtOAc (3 30mL). The combined organic layer was washed
with sat. aq. NaHCO3 (3 10mL) and brine (1 10mL), dried
(MgSO4) and evaporated. The residue was purified by flash chro-
matography (EtOAc:heptane 1:9) to yield the primary alcohol 9 as a
colourless oil. Yield: 0.467 g (65%). Rf¼ 0.35 (EtOAc:heptane 3:7,
KMnO4-stain). 1H NMR (400MHz, CDCl3) d 5.54e5.44 (m, 1H), 5.36
(broad dd, J¼ 15.3, 6.8, 1H), 4.00 (q, J¼ 6.4 Hz, 1H), 3.63 (t,
J¼ 6.6 Hz, 2H), 1.98 (q, J¼ 7.9, 7.4 Hz, 2H), 1.60e1.52 (m, 2H),
1.52e1.21 (m, 20H), 0.92e0.84 (m, 3H), 0.88 (s, 9H), 0.03 (s, 3H),
0.01 (s, 3H). 13C NMR (101MHz, CDCl3) d 133.9, 130.5, 74.0, 63.2,
38.7, 32.9, 32.2, 31.5, 29.7, 29.7, 29.5, 29.1, 26.1 (3xC), 25.9, 25.6, 22.7,
18.4, 14.2, 4.0, 4.6. Exact mass calculated for C22H46O2SiNa
[MþNa]þ: 393.3159, found 393.3159.4.1.7. (E)-9-Hydroxyhexadec-10-enoic acid (10)
Alcohol 9 (1.53mmol, 0.566 g, 1.00 equiv.) was dissolved in
CH2Cl2 (15.0mL) and added NaHCO3 (0.39 g, 3.00mmol) and Dess-
Martin Periodinane (1.84mmol, 0.780 g, 1.2 equiv.). The mixture
was stirred at room temperature for 1.5 h and then filtered through
a plug of silica gel that was washed with a small amount of EtOA-
c:heptane (1:4). The residue was dissolved in MeCN (15.0mL) and
2-methyl-2-butene (3.60mL). Then a solution of NaH2PO4
(6.00mmol, 0.722 g, 7.00 equiv.) in water (6.00mL) was added.
Finally, 80% NaClO2 (7.74mmol, 0.872 g, 9.00 equiv.) was added and
the mixture was stirred vigorously for 80min. Then sat. aq.
NaH2PO4 (50mL) was added and the mixture was extracted with
EtOAc (3 20mL). The combined organic extracts were washed
with water (1 10mL), dried (Na2SO4) and evaporated. The
resulting residuewas taken through a short plug of silica gel eluting
with CH2Cl2:MeOH (19:1). The residue was dissolved in dry THF
(5.0mL) and added a solution of TBAF (10.0mL, 1.0M in THF) at
0 C. The mixture was stirred at room temperature overnight. Sat.
aq. NaH2PO4 (50mL) was added and the mixture was extracted
with EtOAc (2 30mL). The combined organic layers were washed
with brine, dried (Na2SO4) and evaporated. The residue was puri-
fied by flash chromatography using a gradient of 5e70% EtOAc in
heptane to afford the desired product 10 as a colourless wax. Yield:
156mg (67%). Rf¼ 0.46 (DCM:MeOH:AcOH 20:1:0.1, KMnO4-stain).
1H NMR (400MHz, CDCl3) d 5.69e5.57 (m, 1H), 5.44 (ddt, J¼ 15.3,
7.2, 1.4 Hz, 1H), 4.03 (q, J¼ 6.7 Hz, 1H), 2.33 (t, J¼ 7.5 Hz, 2H), 2.01
(q, J¼ 6.9, 2H), 1.70e1.42 (m, 4H), 1.42e1.20 (m, 15H), 0.88 (t,
J¼ 6.9 Hz, 3H). 13C NMR (101MHz, CDCl3) d 179.6, 133.0, 132.5, 73.4,
33.7, 34.6, 32.3, 31.5, 29.5, 29.3, 29.3, 29.1, 29.0, 25.5, 24.8, 22.7, 14.2.
Exact mass calculated for C16H30O3Na [MþNa]þ: 293.2087, found
293.2088.4.1.8. (E)-9-Oxohexadec-10-enoic acid (2)
Alcohol 10 (79mg, 0.30mmol) was dissolved in dry CH2Cl2
(20mL) and added celite (600mg), MnO2 (85%, 4.4mmol, 450mg)
and the resulting mixture was stirred 20 h at room temperature.
The mixture was filtered through a plug of celite that was washed
with EtOAc. The filtrate was evaporated and purified by column
chromatography on silica gel (heptane/EtOAc 70:30, then 60:40) to
afford the title compound 2 as a pale yellow wax. Yield: 12mg
(15%). Rf¼ 0.34 (CH2Cl2/MeOH/AcOH 20:1:0.1, CAM stain). 1H NMR
(400MHz, CDCl3) d 6.82 (dt, J¼ 15.8, 6.9 Hz, 1H), 6.08 (dt, J¼ 15.7,
1.5 Hz, 1H), 2.52 (t, J¼ 7.4 Hz, 2H), 2.34 (t, J¼ 7.5 Hz, 2H), 2.20 (qd,
J¼ 7.0, 1.5 Hz, 2H), 1.61 (m, 4H), 1.45 (m, 2H), 1.37e1.28 (m, 10H),
0.91e0.87 (t, J¼ 6,8 Hz, 3H). 13C NMR (101MHz, CDCl3) d 201.1,
178.6, 147.6, 130.4, 40.1, 33.9, 32.6, 31.5, 29.23, 3.19, 29.0, 27.9, 24.8,
24.3, 22.6, 14.1. Exact mass calculated for C16H28O3Na [MþNa]þ:
291.1931, found 291.1930.4.2. Biology
4.2.1. Plasmids
The pSG5-Gal4-hPPARa-LBD, pSG5-Gal4-hPPARd-LBD, and
pSG5-Gal4-hPPARg-LBD encoding Gal4 DNA-binding domain
(DBD; aa 1-147) fused in frame with the SV40 nuclear localization
signal 1 (NLS1), and ligand binding domain (LBD) of human PPARa
(aa 168-468), PPARd (aa 140-441), and PPARg (aa 205-505) has
been described earlier [14]. pSG-Gal4 encoding Gal4 DBD and SV40
NLS1 was made by amplifying this part of the pSG5-Gal4-hPPARd-
LBD, using a custom-made reverse primer thatmade up the original
multi cloning site (MCS): KpnI-XmaI-NotI-EagI-SacII-BamHI-BglII.
This PCR product was then subcloned between XhoI and BamHI
in pSG5-Gal4-hPPARd-LBD, exchanging PPARd-LBD with the new
MCS. pSG5-Gal4-hLXRa-LBD, pSG5-Gal4-hLXRb-LBD, and pSG5-
Gal4-hRXRa-LBD encoding Gal4 DBD, SV40 NLS1, and the LBDs of
human LXRa (aa 164-447), LXRb (aa 155-461), and RXRa (aa 202-
462) were made by PCR amplifying the respective LBDs and sub-
cloning them into pSG-Gal4 between KpnI and BamHI (LXRa and
-b) or KpnI and SacII (RXRa). The plasmids encoding FLAG-tagged
full-length human PPARa, PPARg, and RXRa have been described
earlier [14,55]. The pGL3-5UAS-SV40 luciferase reporter, as well
as the human PLIN1-driven reporters, pGL3-hPLIN1-30del and
pGL3-hPLIN1-30del PPREmut, have been described before [9,14].
The human CPT1A-driven reporters, pGL3-hCPT1AInt and pGL3-
hCPT1AInt PPREmut, were received as a gift from Prof. Diego
Haro Bautista and have been described previously [56]. The vector
pRL-CMV (Promega, Madison, WI), constitutively expressing
Renilla Luciferase, was used as a control of transfection efficiency.
All cloned plasmids have been sequenced. Cloning primer se-
quences are available upon request.
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COS-1 cells (ATCC® CRL-1650) were maintained in Dulbecco's
modified Eagle's medium (DMEM; D6546, Sigma-Aldrich, St. Louis,
MO) containing penicillin/streptomycin (50 U/mL; 50 mg/mL),
4mM L-glutamine, and 10% fetal bovine serum (F7524; Sigma-
Aldrich), at 37 C in a humidified atmosphere of 5% CO2 in air.
Cell confluence never exceeded 80% before subculturing or trans-
fection. For the dose-response and specificity assays, COS-1 cells
were seeded at 7 104 cells/well in 24-well plates. After 24 h cells
were transfected with either 0.1 mg of the Gal4-DBD-NR-LBD
expression plasmids, 0.2 mg of the 5UAS-SV40 luciferase reporter,
and 0.05 mg of the Renilla Luciferase-coding internal control (pRL-
CMV), or 0.2 mg of the full-length PPAR and RXR-expressing plas-
mids, together with 0.2 mg of any of the PLIN1- or CPT1A-driven
reporters, and 0.05 mg of pRL-CMV using Lipofectamin 2000 (Life
Technologies, Carlsbad, CA). After 5 h the cells were treated with
(7E)-9-oxohexadec-7-enoic acid, (10E)-9-oxohexadec-10-enoic
acid, pirinixic acid (WY-14643; C7081, Sigma-Aldrich), PPARg:
rosiglitazone (BRL-49653; Cayman Chemical, Ann Arbor, MI), or
palmitic acid (C16:0; P0500, Sigma-Aldrich) in DMSO (final conc.
0.1%). After 18 h cells were washed in PBS and lysed in Passive Lysis
Buffer (Promega, Madison,WI) and Dual-Luciferase® ReporterAssay
System (Promega) was run on a Synergy 2 plate reader (BioTek®
Instruments, Winooski, VT) following the manufacturers protocol.
The Firefly Luciferase readings were normalized to the Renilla
Luciferase numbers and data from at least three independent
transfection experiments run in quadruplicate are presented.
Huh-7 human hepatoma cells were maintained in DMEM
(D6546, Sigma-Aldrich) containing penicillin/streptomycin (50 U/
mL; 50 mg/mL), 4mM L-glutamine, 10% fetal bovine serum (F7524;
Sigma-Aldrich), and 0.1% ITS (insulin/transferrin/sodium selenite;
I3146, Sigma-Aldrich), at 37 C in a humidified atmosphere of 5%
CO2 in air. Cell confluence never exceeded 80% before subculturing
or transfection. The cells were seeded at 2 105 cells/well in 12-
well plates. After 24 h cells were treated with 50 mM (7E)-9-
oxohexadec-7-enoic acid, (10E)-9-oxohexadec-10-enoic acid, or
pirinixic acid in DMSO (final conc. 0.1%). On the day after the cells
were washed and scraped in RLT buffer (Qiagen, Hilden, Germany).
Human Simpson-Golabi-Behmel syndrome (SGBS) cells were
cultured and differentiated into adipocytes essentially as described
[32]. Briefly, cells were maintained in basal medium (DMEM/
nutrient mix F-12; D6421, Sigma-Aldrich) supplemented with
2mg/L of biotin, 1mg/L of D-pantothenate, 4mM L-glutamine,
penicillin/streptomycin (50 U/mL; 50 mg/mL), and 10% non-
inactivated fetal calf serum (F7524; Sigma-Aldrich). For adipocyte
differentiation, cells were seeded at low passage (P6-P8) at
0.8 105 cells/well in 12-well plates and grown to confluence (day
0). From day 0 to day 4 the cells were exposed to adipogenic me-
dium (Quickdiff; 3FC supplemented with 25 nM dexamethazone,
0.5mM isobutylmethylxanthine, and 2 mM rosiglitazone, 25 mM 1
(7E)-9-OHE:BSA, or 25 mM 2 (10E)-9-OHE:BSA, followed by
continuous culturing in 3FC (basal medium supplemented with
10 mg/mL human transferrin, 20 nM human insulin,100 nM cortisol,
and 0.2 nM triiodothyronine). Medium was renewed every fourth
day. In a set of separate experiments SGBS cells were differentiated
with Quickdiff medium, including 2 mM rosiglitazone, from day 0 to
day4. Then at day 8 the cells were stimulated with 25 mM 1 (7E)-9-
OHE:BSA, 25 mM 2 (10E)-9-OHE:BSA, or 2 mM rosiglitazone in 3FC
medium for 24 h.
4.2.3. Cytotoxicity assays
The cytotoxic effect of the compounds were evaluated in COS-1
cells, using the Roche Cytotoxicity Detection Kit (#1164479300,
Sigma-Aldrich) measuring lactate dehydrogenase (LDH) leaked
from the cells or by the XTT-based In Vitro Toxicology Assay Kit(#TOX2-1 KT, Sigma-Aldrich) measuring reducedmetabolic NAD(P)
H flux. Both assays were run as described by the company, and
absorbance were read at 492/750 nm and 450/690 nm for the LDH
and XTT assay, respectively, on a Synergy H1 Hybrid Multi-Mode
Microplate Reader (BioTek® Instruments).
4.2.4. Staining of lipids
SGBS cells were washed in PBS, fixed in 4% paraformaldehyde/
PBS for 15 min, washed with PBS, and incubated with Oil Red O for
15 min to stain neutral lipids. Finally, the cells were washed in PBS
to remove excess dye. After staining, the cells were visualized
through 10 and 40 objectives on an Olympus CKX41 inverted
microscope (Olympus, Hamburg, Germany). Images were captured
with a ColorView IIIu light microscope CCD camera (Olympus)
operated by cell* imaging software v.3.4 (Olympus). Images were
processed with Adobe Photoshop CS6 (Adobe Systems Inc. San Jose
California, USA).
4.2.5. RNA extraction, cDNA synthesis and real-time quantitative
PCR (qPCR)
RNA was isolated using the RNeasy Mini kit (#74104, Qiagen)
with the following modifications: Lysates from cells with high-fat
content, such as SGBS cells on day 8 and 12, were mixed 1:1 in
70% ethanol in high salt solution (0.45M NaCl/0.24M Na-acetate),
before applied to the columns. Isolated RNA (500 ng) was reverse
transcribed into cDNA using SuperScript III Reverse Transcriptase
(Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) and
random hexamer primers. qPCR was performed with 2.5 mL cDNA,
equivalent to 12.5 ng RNA, in a 10 mL reaction mix using Kapa SYBR
FAST qPCRMaster Mix (KapaBiosystems, Roche, Basel, Switzerland)
on a Bio-Rad CFX96 Touch™ Real-Time PCR Detection System. Gene
expression was normalized against the expression of TATA-binding
protein (TBP). Assay primers were designed with Primer-BLAST
software (NCBI, Bethesda, MD, USA) [57]. Primer sequences are
listed in Suppl. Table S1.
4.2.6. RNA-sequencing
SGBS cells were differentiated in Quickdiff and 3FC medium for
4 plus 4 days, respectively, following the protocol described above.
The Quickdiff media was supplemented with either 2 mM rosigli-
tazone (n¼ 4), 25 mM 1 (7E)-9-OHE:BSA (n¼ 4), or 25 mM 2 (10E)-9-
OHE:BSA (n¼ 2). Undifferentiated SGBS cells, grown to confluence
(day 0), were also assayed (n¼ 2). The SGBS cells were lysed in RTL
buffer and total RNA extracted using RNeasy Mini kit (Qiagen). RNA
quality was assessed on a BioAnalyzer 2100, using the Agilent RNA
6000 Nano Kit (#5067-1511; Agilent Technologies Inc, Santa Clara,
CA). The RIN values (RNA integrity number) varied between 9.80
and 10.00, with an average of 9.95. Illumina sequencing libraries
were prepared according to the strand-specific TruSeq RNA Sample
Preparation Guide (revision D) and sequencing performed on a
NextSeq 500 (Illumina, San Diego, CA), using v2 reagents. Libraries
were sequenced using 2 75 bp paired-end reads. For pre-
alignment quality control, we used the software FastQC v0.10.1.
Themean library size was ~18million read pairs, with no difference
between groups or time points. Alignment of cDNA sequenced
reads was done using Tophat v2.0.8, Samtools v0.1.18, and Bowtie
v2.1.0 with default settings against the UCSC hg19 annotated
transcriptome and genome. Reads were counted by Cufflinks v2.1.1
and presented as Reads Per Kilobase of transcript per Million
mapped reads (RPKM). Differentially expressed genes were iden-
tified using one-way anova and an RPKM cut-off set to 5.
4.2.7. Accession number
Accession number for the RNA-seq data reported in this article is
NCBI GEO GSE115827.
T. Sæther et al. / European Journal of Medicinal Chemistry 155 (2018) 736e7537524.2.8. Statistical analysis
Statistical analyses were performed using GraphPad Prism 6
(GraphPad Software Inc., San Diego, CA, USA). All data are presented
as mean and standard error of the mean (SEM) or standard devia-
tion (SD). Statistical differences between groups were determined
by two-way analysis of variance (ANOVA) followed by Tukey's
multiple comparison tests. For all statistical tests p< 0.05 was
considered statistically. Any exceptions to this are given in the
Figure legends.
4.2.9. Venn diagrams
Top 500 differentially expressed genes in our dataset, using
mean of replicates, were visualized using the Venn diagram
drawing tool from Bioinformatics & Evolutionary Genomics, Ghent
University, Belgium (http://bioinformatics.psb.ugent.be/webtools/
Venn).
4.2.10. Principal component analysis
Principal component analysis (PCA) of the 8274 differentially
expressed genes in our dataset was made with Clustvis, a web tool
for visualizing clustering of multivariate data (https://biit.cs.ut.ee/
clustvis) [58]. Row scaling was made by unit variance scaling
(UVS) and missing data imputation was made using singular value
decomposition (SVD).
4.2.11. Pathway enrichment analysis
Pathway enrichment analysis of the top 500 differentially up-
and downregulated genes, using mean of replicates, were made
with the ConsensusPathDB tool from the Max-Planck-Institute for
Molecular Genetics (http://cpdb.molgen.mpg.de) [59], using the
Kyoto Encyclopedia of Genes and Genomes (KEGG) gene sets v80.0,
pathway ID: 00000-05000 excluding non-relevant human dis-
eases. Minimum overlap with input list was set to 3 and the p-value
cutoff to p< 0.01.
Notes
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